CN1636598A - 加强静脉内雌莫司汀磷酸盐作用的方法 - Google Patents
加强静脉内雌莫司汀磷酸盐作用的方法 Download PDFInfo
- Publication number
- CN1636598A CN1636598A CNA2004100867183A CN200410086718A CN1636598A CN 1636598 A CN1636598 A CN 1636598A CN A2004100867183 A CNA2004100867183 A CN A2004100867183A CN 200410086718 A CN200410086718 A CN 200410086718A CN 1636598 A CN1636598 A CN 1636598A
- Authority
- CN
- China
- Prior art keywords
- estramustine
- cancer
- estramustine phosphate
- carcinoma
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 title claims abstract description 132
- 229960004750 estramustine phosphate Drugs 0.000 title claims abstract description 127
- 238000001990 intravenous administration Methods 0.000 title claims abstract description 69
- 238000000034 method Methods 0.000 title claims abstract description 65
- 230000003389 potentiating effect Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 32
- 238000011282 treatment Methods 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 201000011510 cancer Diseases 0.000 claims abstract description 20
- 238000009472 formulation Methods 0.000 claims abstract description 19
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 17
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 11
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 11
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 10
- 201000003733 ovarian melanoma Diseases 0.000 claims abstract 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims description 72
- 229960001842 estramustine Drugs 0.000 claims description 72
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 38
- AXWYROHIFVWHMR-UGTOYMOASA-N [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] n,n-bis(2-chloroethyl)carbamate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AXWYROHIFVWHMR-UGTOYMOASA-N 0.000 claims description 23
- 238000001802 infusion Methods 0.000 claims description 22
- 201000001514 prostate carcinoma Diseases 0.000 claims description 17
- 239000002207 metabolite Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 13
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 12
- 201000008275 breast carcinoma Diseases 0.000 claims description 10
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 8
- 230000002085 persistent effect Effects 0.000 claims description 8
- 239000003080 antimitotic agent Substances 0.000 claims description 7
- 229940123237 Taxane Drugs 0.000 claims description 5
- 229940044684 anti-microtubule agent Drugs 0.000 claims description 5
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 5
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 2
- 229930195573 Amycin Natural products 0.000 claims description 2
- 230000037058 blood plasma level Effects 0.000 claims 4
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 229940124650 anti-cancer therapies Drugs 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 abstract description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 5
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 230000002927 anti-mitotic effect Effects 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 108010048134 estramustine-binding protein Proteins 0.000 description 14
- 210000003462 vein Anatomy 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 9
- 102100038358 Prostate-specific antigen Human genes 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 230000003442 weekly effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 6
- 210000002307 prostate Anatomy 0.000 description 6
- 231100000167 toxic agent Toxicity 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 102000029749 Microtubule Human genes 0.000 description 4
- 108091022875 Microtubule Proteins 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 229960003399 estrone Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 201000002327 urinary tract obstruction Diseases 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 238000009448 modified atmosphere packaging Methods 0.000 description 2
- 235000019837 monoammonium phosphate Nutrition 0.000 description 2
- 238000002625 monoclonal antibody therapy Methods 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 201000005060 thrombophlebitis Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000016247 Soft tissue disease Diseases 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001946 anti-microtubular Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 229910052614 beryl Inorganic materials 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- -1 chlormethine carbamate derivatives Chemical class 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002642 intravenous therapy Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 210000002239 ischium bone Anatomy 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7954298P | 1998-03-27 | 1998-03-27 | |
| US60/079,542 | 1998-03-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99800823A Division CN1273530A (zh) | 1998-03-27 | 1999-03-26 | 加强静脉内雌莫司汀磷酸盐作用的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1636598A true CN1636598A (zh) | 2005-07-13 |
Family
ID=22151209
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004100867183A Pending CN1636598A (zh) | 1998-03-27 | 1999-03-26 | 加强静脉内雌莫司汀磷酸盐作用的方法 |
| CN99800823A Pending CN1273530A (zh) | 1998-03-27 | 1999-03-26 | 加强静脉内雌莫司汀磷酸盐作用的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99800823A Pending CN1273530A (zh) | 1998-03-27 | 1999-03-26 | 加强静脉内雌莫司汀磷酸盐作用的方法 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1003521A4 (xx) |
| JP (1) | JP2001508810A (xx) |
| KR (1) | KR20010021656A (xx) |
| CN (2) | CN1636598A (xx) |
| AU (1) | AU750010B2 (xx) |
| BR (1) | BR9906425A (xx) |
| CA (1) | CA2295049A1 (xx) |
| EA (1) | EA004647B1 (xx) |
| HU (1) | HUP0200547A3 (xx) |
| ID (1) | ID24504A (xx) |
| IL (1) | IL133612A0 (xx) |
| NO (1) | NO20002343D0 (xx) |
| NZ (1) | NZ501987A (xx) |
| PL (1) | PL342969A1 (xx) |
| WO (1) | WO1999049869A1 (xx) |
| ZA (1) | ZA997821B (xx) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003201D0 (en) * | 2000-02-11 | 2000-04-05 | Pharmacia & Upjohn Spa | Method to potentiate the therapeutic efficacy of taxane and derivatives thereof |
| US6436913B1 (en) * | 2000-07-25 | 2002-08-20 | Pharmacia & Upjohn Company | Use of estramustine phosphate in the treatment of bone metastasis |
| RU2471511C1 (ru) * | 2011-05-04 | 2013-01-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "РНИОИ" Минздравсоцразвития России) | Способ лечения метастазов в печень рака толстой кишки |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS617292A (ja) * | 1984-06-20 | 1986-01-13 | Japan Atom Energy Res Inst | 制癌剤を結合させたエストラサイト系化合物を製造する方法 |
| US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| MX9203808A (es) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| EP0706373B1 (en) * | 1992-03-23 | 2000-07-19 | Georgetown University | Liposome encapsulated taxol and a method of using the same |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
-
1999
- 1999-03-26 AU AU33533/99A patent/AU750010B2/en not_active Ceased
- 1999-03-26 ID IDW20000105A patent/ID24504A/id unknown
- 1999-03-26 KR KR1020007000214A patent/KR20010021656A/ko not_active Application Discontinuation
- 1999-03-26 IL IL13361299A patent/IL133612A0/xx not_active IP Right Cessation
- 1999-03-26 EP EP99914884A patent/EP1003521A4/en not_active Withdrawn
- 1999-03-26 JP JP54936999A patent/JP2001508810A/ja not_active Ceased
- 1999-03-26 HU HU0200547A patent/HUP0200547A3/hu unknown
- 1999-03-26 PL PL99342969A patent/PL342969A1/xx unknown
- 1999-03-26 CA CA002295049A patent/CA2295049A1/en not_active Abandoned
- 1999-03-26 NZ NZ501987A patent/NZ501987A/xx unknown
- 1999-03-26 CN CNA2004100867183A patent/CN1636598A/zh active Pending
- 1999-03-26 CN CN99800823A patent/CN1273530A/zh active Pending
- 1999-03-26 BR BR9906425-1A patent/BR9906425A/pt not_active IP Right Cessation
- 1999-03-26 WO PCT/US1999/004275 patent/WO1999049869A1/en not_active Application Discontinuation
- 1999-03-26 EA EA199901081A patent/EA004647B1/ru not_active IP Right Cessation
- 1999-12-22 ZA ZA9907821A patent/ZA997821B/xx unknown
-
2000
- 2000-05-04 NO NO20002343A patent/NO20002343D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20002343L (no) | 2000-05-04 |
| AU3353399A (en) | 1999-10-18 |
| EA199901081A1 (ru) | 2000-12-25 |
| ZA997821B (en) | 2000-08-01 |
| ID24504A (id) | 2000-07-20 |
| AU750010B2 (en) | 2002-07-11 |
| NZ501987A (en) | 2002-10-25 |
| WO1999049869A1 (en) | 1999-10-07 |
| HUP0200547A3 (en) | 2003-07-28 |
| CN1273530A (zh) | 2000-11-15 |
| EP1003521A4 (en) | 2003-07-23 |
| HUP0200547A2 (hu) | 2002-07-29 |
| JP2001508810A (ja) | 2001-07-03 |
| NO20002343D0 (no) | 2000-05-04 |
| BR9906425A (pt) | 2000-07-11 |
| EP1003521A1 (en) | 2000-05-31 |
| PL342969A1 (en) | 2001-07-16 |
| KR20010021656A (ko) | 2001-03-15 |
| CA2295049A1 (en) | 1999-10-07 |
| EA004647B1 (ru) | 2004-06-24 |
| IL133612A0 (en) | 2001-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ren et al. | Diversified strategies based on nanoscale metal-organic frameworks for cancer therapy: The leap from monofunctional to versatile | |
| US20140294964A1 (en) | Compositions and methods for treating cancer with dacarbazine nanoemulsions | |
| JP2007518805A5 (xx) | ||
| Liu et al. | Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent | |
| CN104368004A (zh) | 一种用于运载抗肿瘤药物的核酸纳米结构及其制备方法和应用 | |
| CN110403916B (zh) | 一种纳米治疗剂及其制备方法与应用 | |
| WO2023015887A1 (zh) | 一种槲皮素铁离子胶束及其在肿瘤光热免疫治疗中的应用 | |
| Sun et al. | Alendronate PtIV prodrug amphiphile for enhanced chemotherapy targeting and bone destruction inhibition in osteosarcoma | |
| FR2904554A1 (fr) | Lipides moleculaires heterogenes cytotropes (lmhc), procede de preparation, et methodes de traitement de patients proteurs de cancers multiples | |
| Gao et al. | Cancer Nanobombs Delivering Artoxplatin with a Polyigniter Bearing Hydrophobic Ferrocene Units Upregulate PD‐L1 Expression and Stimulate Stronger Anticancer Immunity | |
| CN106692059A (zh) | 一种低氧响应脂质体药物载体及其制备方法与应用 | |
| CN111494338B (zh) | 化疗与光动力治疗协同作用的卵清蛋白纳米胶囊及其制备方法和应用 | |
| CN1636598A (zh) | 加强静脉内雌莫司汀磷酸盐作用的方法 | |
| CN109730976B (zh) | 一种基于自由基氧化制备白蛋白纳米粒的方法 | |
| CN104546722B (zh) | 米铂脂质体和制法 | |
| CN103735504A (zh) | 一种伊立替康纳米脂束制剂及其制备方法 | |
| TW201726179A (zh) | 純化方法 | |
| CN109419773B (zh) | 复合纳米脂质给药系统及其对妇科肿瘤的治疗作用 | |
| CN108926719B (zh) | 用c(RGD-ACP-K)修饰的长循环脂质体 | |
| US6849616B1 (en) | Methods to potentiate intravenous estramustine phosphate | |
| CN101559039B (zh) | 利用植物甾醇生产纳豆激酶脂质体的方法 | |
| CN1511037A (zh) | 非肠道使用的雌莫司汀磷酸盐和白蛋白的制剂 | |
| CN115068615B (zh) | 一种“开源节流”型逆转乏氧抗肿瘤药物组合物及其应用 | |
| CN1177583C (zh) | 具有改进药理学性质的非肠胃道使用的雌莫司汀磷酸盐制剂 | |
| CN115381838B (zh) | 一种用于低氧点亮和外周/中心闭环根除肿瘤的纳米组装体及制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |